Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC.Methods: A con...

Full description

Bibliographic Details
Main Authors: Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
lenvatinib
hepatitis B virus
hepatitis C virus
antiviral therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1032881/full

Similar Items

Similar Items